SCHEMBL3383215

SCHEMBL3383215

O=C(NCCCCCC(=O)c1ccc(-c2ccccc2)cc1)Nc1ccccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 10/20 0.55
HDAC3 O15379 7/20 0.55
HDAC8 Q9BY41 6/20 0.55
HDAC2 Q92769 6/20 0.55
HDAC4 P56524 5/20 0.55
HDAC7 Q8WUI4 5/20 0.55
HDAC10 Q969S8 5/20 0.55
HDAC11 Q96DB2 5/20 0.55
HDAC6 Q9UBN7 5/20 0.55
HDAC9 Q9UKV0 5/20 0.55
HDAC5 Q9UQL6 5/20 0.55
MARS1 P56192 1/20 0.46
PPARG P37231 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
RAB9A P51151 2/20 0.44
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13784010 0.92 L3MBTL1 (0.54) HDAC1HDAC3HDAC8HDAC2HDAC4
SCHEMBL13783882 0.87 KMT2A (0.60) HDAC1HDAC3HDAC8HDAC2HDAC4
SCHEMBL3383033 0.87 HDAC1 (0.74) HDAC1HDAC3HDAC8HDAC2HDAC4
SCHEMBL3383132 0.85 HDAC1 (0.74) HDAC1HDAC3HDAC8HDAC2HDAC4
SCHEMBL7096384 0.79 HDAC1 (0.49) HDAC1HDAC3HDAC8HDAC2HDAC4
SCHEMBL3383335 0.79 HDAC1 (0.71) HDAC1HDAC3HDAC8HDAC2HDAC4
SCHEMBL7093746 0.77 MARS1 (0.50) HDAC1HDAC3HDAC8HDAC2HDAC4
SCHEMBL3384155 0.76 HDAC1 (0.72) HDAC1HDAC3HDAC8HDAC2HDAC4
SCHEMBL8389275 0.76 EPHX1 (0.66) MARS1L3MBTL1
SCHEMBL8778001 0.76 EPHX1 (0.66) MARS1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280764-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2010-11-24 EP disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-7288567-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2007-10-30 US disclosed
US-7288567-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2007-10-30 US disclosed
EP-1524262-A1 Inhibitors of histone deacetylase Methylgene, Inc. (CA) 2005-04-20 EP disclosed
US-20020115826-A1 Inhibitors of histone deacetylase 92229129 QUEBEC INC. (CA) 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115826-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 HDAC1 1/4885HDAC3 3/4885HDAC8 9/4885
US-20090181971-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 HDAC1 1/4885HDAC3 3/4885HDAC8 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.